NeurologyLive Friday 5 — March 19, 2021

March 19, 2021
NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA), in this episode of this Cure Connections series, "Cure SMA: Evaluation of SMA in the Era of Telehealth."

2: Obstructive Sleep Apnea: Stopping the “Loud Killer”

William H. Noah, MD, writes that if hypertension is the silent killer, then snoring—and its accompanied condition, obstructive sleep apnea—is the loud killer. Raising awareness of OSA on World Sleep Day is of utmost importance.

3: NeuroVoices: Anne Kever, PhD, on MS Diagnosis Disclosure, Concealment Behaviors

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.

4: Donanemab Slows Decline on iADRS in Early Alzheimer Disease, Mixed Secondary Outcomes

Despite showing better composite scores for cognition and ability to perform activities of daily living, a number of the secondary outcomes showed mixed results with the Eli Lilly investigational agent.

5: COVID-19 and Muscular Dystrophies, and R&D for Rare Disorders: Sharon Hesterlee, PhD

The executive vice president and chief research officer of the MDA offered her perspective on the ongoing conversations about and impact of the pandemic on the care of patients with muscular dystrophies.

In Case You Missed It: Coverage of the virtual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021 is still ongoing! To check back in to see the latest data presentations and interviews with investigators and opinion leaders, and more, click here.